Ruxolitinib for myelofibrosis: The earlier, the better?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39396121.
- Also identified by DOI 10.1002/cncr.35592 and PMC identifier 12007918.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is mounting evidence to support the use of ruxolitinib earlier in the disease course of MF. Use in intermediate-1 risk MF is generally associated with higher efficacy and lower toxicity.